Belfast City Hospital

Assessing the DNA methylation inhibitory effects of 5-azacytidine on cardiac relevant genes: a pilot study

An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1

A proof-of-mechanism and proof-of-concept clinical trial evaluating the safety, tolerability, biological and anti-tumour activity of apalutamide with dual CXCR1 and CXCR2 blockade by SX-682 for men suffering from metastatic castration-resistant prostate cancer (mCRPC)

Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer

A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer

CV6-168 – A First in Human Modular, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of the specific dUTPase inhibitor CV6-168 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies

Developing ctDNA guided adjuvant therapy for gastrooesophageal cancer.
A single arm phase II trial of trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma cancer who are ctDNA and HER2 positive

Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly-defined Indications using a National Evaluation platform trial

Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women

Feasibility of a co-designed lifestyle intervention during treatment for advanced colorectal cancer: a single centre pilot.

A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost
radiotherapy against a standard 3-week schedule in patients with early breast cancer

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer

Investigation of Circulating Haematological Biomarkers in Cancer

The interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project

Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain

A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera

The ModiFY Study: A phase 1/2, multicentre, open‐label study of Modi‐1 in patients with breast, head and neck, ovarian, or renal cancer

Optimising Therapy in FLT3-mutated Acute Myeloid Leukaemia

Power of liquid biopsy tracking in immunotherapy treated stage IV melanoma

Prospective Observational Study Of Treatment And Outcomes For Patients With Newly Diagnosed Follicular Lymphoma

A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition with or without anti-PD-L1 immunotherapy in patients with neoadjuvant treatment resistant residual triple negative breast cancer

A Multicentre Open Label Randomised Phase III Trial Comparing Extended Nodal Irradiation with Stereotactic Body Radiotherapy for oligo-recurrent pelvic nodal prostate cancer

Prospective, Randomised, Multicentre Trial of First-Line Systemic Treatment And Radiotherapy In Stage IV Non-Small Cell Lung Cancer

A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma

Quality of Life After Radiotherapy Treatment For Patients With Stage IV Non-Small Cell Lung Cancer

A randomised open-label phase III trial of Reduced Frequency pembrolizumab immunotherapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design

A randomised phase II trial of investigator choice standard therapy versus sequential novel therapy experimental arms in relapsed and refractory follicular lymphoma

Real-world Evaluation of Patient Outcomes and Experiences with Ribociclib Early Adopters: A Hybrid Study with Prospective Patient-reported Outcomes and Retrospective Clinical Chart Review

Real-World Outcomes of DArolutamide, ADT, with or without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Adjuvant Radiotherapy in Patients with High-risk Primary Cutaneous Squamous Cell Carcinoma AFTER surgery (SCC-AFTER): An Open Label, Multicentre, Two-arm Phase III Randomised trial

A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision

A phase II, randomiSed study of CHOP-R in combination with acalabruTinib comparEd to CHOP-R in patients with newLy diagnosed Richter’s Syndrome and a pLAtfoRm for initial investigations into activity of novel treatments in relapsed/refractory and newly diagnosed Richter’s Syndrome

A Phase 2, Open-Label, Randomised Study To Evaluate Prophylactic Interventions On Talquetamab-Related Oral Toxicity

Tumour Characterization to Guide Experiential Targeted Therapy – National

Thoracic Umbrella Radiotherapy Study In Stage IV NSCLC

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously with i) first-line standard of care nab-paclitaxel and gemcitabine, or ii) in combination with MEK inhibitor maintenance therapy

A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Venetoclax or Intensive Chemotherapy For Treatment of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study